Mitotane drug introduction

Mitotane (Mitotane) is a drug used to treat adrenocortical cancer. As a lipase inducer, it mainly inhibits the proliferation and spread of cancer cells by inhibiting the synthesis and release of adrenocortical hormones, thereby achieving therapeutic effects.

The mechanism of action of mitotane is multifactorial. First, it inhibits the chromograninP450system of mitochondria in adrenocortical cells, especiallyCYP11A1 (cholesterol side chain cleavage enzyme) andCYP11B1 (11β-hydroxylase) activity interferes with the cholesterol metabolism pathway, thereby reducing levels of hormones such as cortisol, aldosterone and androgens. This stops the growth and proliferation of cancer cells while prompting them to enter an apoptotic state.

In addition,mitotane may also affect mitochondrial function by affecting intracellularROS (reactive oxygen species) levels, thereby inducing apoptosis of adrenocortical cancer cells. It may also inhibit the growth and spread of tumors by affecting the function of adrenocortical cells, such as reducing hormone secretion, changing the growth and differentiation status of cells, etc.

In clinical practice,mitotane is often used as first-line treatment for long-term treatment of adrenocortical cancer. Although its efficacy is not 100%, in some cases it can effectively slow down tumor growth and prolong patient survival. However, the use of Mitotane is also associated with certain side effects, including nausea, vomiting, diarrhea, rash, fatigue, etc. In severe cases, it may lead to liver function damage, thyroid dysfunction, etc.

In general, Mitotane is a first-line drug for the treatment of adrenocortical cancer. Although its efficacy may be limited, it can help patients control the disease and improve survival rate to a certain extent. However, patients should pay close attention to possible side effects when using mitotane (mitotane), and conduct reasonable medication and management under the guidance of a doctor.